Search
News & Events
The Kids Research Institute Australia researchers take out prestigious Premier’s Science AwardsThree outstanding researchers have won 2023 Premier’s Science Awards, with another inducted into the prestigious WA Science Hall of Fame.
News & Events
The Kids Research Institute Australia researchers awarded $11 million to support vital child health researchResearchers from The Kids Research Institute Australia have been awarded more than $11 million to support vital child health projects, under the Federal Government’s Medical Research Future Fund.
News & Events
International clinical trial reduced lung inflammation in young kids with cystic fibrosisPromising results from an Australian-led clinical trial could drastically change the way we care for young children with cystic fibrosis (CF).
News & Events
Raine Foundation grants to support key child health researchThree outstanding young researchers from The Kids Research Institute Australia have been named Raine Fellows and received valuable Raine Priming Grants to support their child health research.
News & Events
The Kids researchers named as finalists in 2021 Premier’s Science AwardsFour The Kids Research Institute Australia researchers – working across diverse fields including paediatric anaesthesia, bioinformatics, ear health, and the health impacts of biodiesel exhaust – have been named as finalists in the 2021 Premier’s Science Awards.
News & Events
Four The Kids researchers in running for West Australian of the Year AwardsFour outstanding The Kids Research Institute Australia researchers, including Institute Director, Professor Jonathan Carapetis AM, have been named finalists in the 2021 Western Australian of the Year Awards.
Research
Finding the optimal regimen for Mycobacteroides abscessus treatment (FORMaT) in people with Mycobacteroides abscessus pulmonary diseaseMycobacteroides abscessus (MABS) is within the non-tuberculous mycobacteria family. It inhabits soil and water, exhibits multi-antibiotic resistance and causes opportunistic lung infections, which may progress to symptomatic MABS-pulmonary disease (MABS-PD) associated with substantial morbidity, increased healthcare utilisation, impaired quality of life and increased mortality.
Research
Intrauterine growth restriction promotes hypothalamic circadian dysregulation in adult mouse offspringAdverse prenatal conditions can induce intrauterine growth restriction and increase the risk of adulthood metabolic disease. Mechanisms underlying developmentally programmed metabolic disease remain unclear but may involve disrupted postnatal circadian rhythms and kisspeptin signalling.
Research
Pulmonary bacteriophage and cystic fibrosis airway mucus: friends or foes?For those born with cystic fibrosis (CF), hyper-concentrated mucus with a dysfunctional structure significantly impacts CF airways, providing a perfect environment for bacterial colonization and subsequent chronic infection. Early treatment with antibiotics limits the prevalence of bacterial pathogens but permanently alters the CF airway microenvironment, resulting in antibiotic resistance and other long-term consequences.
Research
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trialRepurposed drugs with host-directed antiviral and immunomodulatory properties have shown promise in the treatment of COVID-19, but few trials have studied combinations of these agents. The aim of this trial was to assess the effectiveness of affordable, widely available, repurposed drugs used in combination for treatment of COVID-19, which may be particularly relevant to low-resource countries.